Investments
AIQ Solutions Inc., Madison, Wisconsin, USA
AIQ Solutions provides an AI-powered software solution for the automated assessment of therapy
response in patients with late-stage cancer. This significantly improves the individual selection of
remaining therapy options in late-stage tumors and enhances prognostic evaluation.
Nuclide Therapeutics Ltd., London, UK
Nuclide Therapeutics develops radiopharmaceuticals targeting tumor stem cells which mediate
resistance to chemo- or radiotherapy. The therapeutic principle is based on a tumor-agnostic
mechanism hitherto not addressed.
WM Therapeutics AG, Heidelberg, Germany
WMT develops active ingredients with a unique novel mechanism of action, known as „translational
trap,“ to date not exploited globally. The mechanism shows promise to treat viral infections,
inflammatory diseases, and cancer.
For Prospective Investments
- You are a founder, researcher, or inventor of groundbreaking new technologies which you would like to develop and commercialize in the framework of an own company.
- You are looking for a financing partner understanding and valuing outstanding scientific achievements with potential to solve fundamental problems.
- You are seeking an interdisciplinary partnership at eye level which is not afraid of ambitious goals.